Literature DB >> 10203614

Usefulness of p53 protein, Bcl-2 protein and Ki-67 as predictors of chemosensitivity of malignant tumors.

M Itaya1, J Yoshimoto, K Kojima, S Futagawa.   

Abstract

In various types of human malignant tumors, the presence or absence of expression of apoptosis-associated gene products (p53 protein and Bcl-2 protein) and the tumor proliferation activity-related factor (Ki-67) was assessed by immunohistochemical staining and the correlation between this expression and chemosensitivity to anticancer drugs was investigated. Study subjects comprised 55 preoperative patients with untreated malignant tumors (9 with esophageal cancer, 11 with stomach cancer, 11 with colon cancer, 13 with hepatic cancer and 11 with breast cancer). A chemosensitivity test was carried out with the histoculture drug response assay (HDRA) method using 4 drugs, mitomycin C (MMC), 5-fluorouracil (5-FU), doxorubicin hydrochloride (ADM), and cisplatin (CDDP). Immunohistochemical staining was used to assess expression of p53 protein, Bcl-2 protein and Ki-67. The tumor growth inhibition index (I.I.) of the 4 drugs was significantly lower in a group of the patients with p53 protein overexpression-type (mutant p53 protein positive expression-type) tumors than in a group with p53 protein negative expression-type tumors (p<0.05). No significant correlation was found between the expression of the Bcl-2 protein by and the I.I. of any drug studied in any type of cancer. A negative correlation was found between the labeling index (L.I.) for Ki-67 in all cases and I.I. for MMC and ADM and thus, chemosensitivity of the tumors with high growth activity was lower. Furthermore, a positive correlation existed between the L.I. for Ki-67 and that for p53 protein. The patients with p53 protein overexpression-type (mutant p53 protein positive) tumors showed low chemosensitivity. In addition, overexpression of p53 protein is suggested to be one of the factors involved in the lowered chemosensitivity of the tumors with high growth activity. Summarizing these findings, the p53 protein can play an important role in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203614     DOI: 10.3892/or.6.3.675

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

1.  Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma.

Authors:  Pierluigi Pilati; Simone Mocellin; Carlo R Rossi; Romano Scalerta; Rita Alaggio; Luciano Giacomelli; Cristina Geroni; Donato Nitti; Mario Lise
Journal:  World J Surg       Date:  2003-05-13       Impact factor: 3.352

2.  Effects of treatment with platinum azidothymidine and azidothymidine on telomerase activity and bcl-2 concentration in hepatocellular carcinoma- induced rats.

Authors:  Abdolreza Sabokrouh; Mohammad Taghi Goodarzi; Asad Vaisi-Raygani; Shohreh Khatami; Masoud Taghizadeh-Jahed
Journal:  Avicenna J Med Biotechnol       Date:  2014-10

3.  Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction.

Authors:  Shoumiao Li; Baozhong Li; Jiaxiang Wang; Da Zhang; Zhiqiang Liu; Zhizhong Zhang; Wei Zhang; Yunjie Wang; Dongxiao Bai; Jianyun Guan; Yong Zhang
Journal:  Oncol Res       Date:  2017-01-02       Impact factor: 5.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.